Eli Lilly Halted India Obesity Awareness Campaign Amid Regulatory Scrutiny, Seeks Clarification on Advertising Rules

Eli Lilly Pauses Obesity Awareness Campaign in India Amid Regulatory Concerns

Eli Lilly, the U.S.-based pharmaceutical company, has halted its obesity awareness campaign in India after receiving a warning from the nation's drugs regulator that the campaign may violate rules against advertising prescription medicines to consumers indirectly.

The campaign, titled "We Know Now," was launched in mid-2025, a few months after Lilly introduced its GLP-1 treatment Mounjaro for obesity and diabetes in India. The campaign focused on reframing obesity as a chronic disease rather than a personal failing, featuring newspaper ads, social media posts, billboards, collaborations with Bollywood celebrities, and posters in residential communities. Eli Lilly's corporate logo appeared on the messages, but Mounjaro was not mentioned.

A 16-page letter dated April 10 and sent to the Drugs Controller General of India explained that Lilly had halted the campaign out of regulatory caution following a March advisory from the regulator. Lilly stated that the campaign aimed to help people better understand obesity without naming any product, featuring doctors discussing the condition and urging people to consult their providers for the best advice.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

India, a country of more than 1.4 billion people, has seen a rise in overweight and obesity. A government survey conducted between 2019 and 2021 showed that about 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, up from 20.6% of women and about 19% of men in 2015-2016.

India's drugs regulator in an advisory sent to Eli Lilly in March stated that product advertisements, including surrogate promotions that may indirectly lead consumers to a medicine, are prohibited across media platforms. It said campaigns or influencer engagement that create brand recall or product visibility would be treated as violations.

Comparison of Obesity Market Valuations in India

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The obesity market in India is expected to reach 80 billion rupees ($839.37 million) annually by 2030, from a current valuation of 17.34 billion rupees, according to research firm Pharmarack. Lilly launched Mounjaro in India in March 2025, ahead of Danish rival Novo Nordisk's Indian weight-loss entry. It became the country's top-selling drug in October, while Novo's Wegovy plays catch-up and faces competition from cheaper local generics.

The regulator asked Eli Lilly for a response as to whether it had reviewed the materials for regulatory compliance and what steps it had taken to ensure adherence to drugs rules. Lilly said in the letter that the guidance it received had created "significant regulatory uncertainty" and appeared to restrict even non-branded, doctor-led campaigns.